Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 41 | 2026 | 238 | 7.800 |
Why?
|
| Coronary Vessels | 20 | 2025 | 125 | 3.330 |
Why?
|
| Coronary Artery Disease | 18 | 2025 | 326 | 3.030 |
Why?
|
| Drug-Eluting Stents | 15 | 2017 | 68 | 2.290 |
Why?
|
| Neointima | 9 | 2021 | 21 | 1.630 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2026 | 190 | 1.500 |
Why?
|
| Cerebral Arteries | 2 | 2024 | 45 | 1.420 |
Why?
|
| Angioplasty, Balloon, Coronary | 11 | 2017 | 171 | 1.410 |
Why?
|
| Percutaneous Coronary Intervention | 9 | 2023 | 226 | 1.300 |
Why?
|
| Cerebrovascular Disorders | 2 | 2026 | 89 | 1.120 |
Why?
|
| Intracranial Aneurysm | 6 | 2026 | 384 | 1.030 |
Why?
|
| Plaque, Atherosclerotic | 7 | 2023 | 34 | 1.030 |
Why?
|
| Endovascular Procedures | 5 | 2026 | 634 | 1.020 |
Why?
|
| Optical Imaging | 3 | 2016 | 77 | 0.940 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2017 | 312 | 0.850 |
Why?
|
| Stents | 11 | 2022 | 501 | 0.810 |
Why?
|
| Microscopy | 2 | 2024 | 99 | 0.800 |
Why?
|
| Sirolimus | 9 | 2017 | 93 | 0.780 |
Why?
|
| Carotid Arteries | 2 | 2020 | 64 | 0.740 |
Why?
|
| Algorithms | 6 | 2014 | 1059 | 0.730 |
Why?
|
| Coronary Angiography | 11 | 2023 | 212 | 0.720 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2024 | 141 | 0.710 |
Why?
|
| Predictive Value of Tests | 12 | 2025 | 1117 | 0.680 |
Why?
|
| Coronary Restenosis | 6 | 2017 | 21 | 0.670 |
Why?
|
| Vertebral Artery | 1 | 2020 | 29 | 0.630 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2020 | 34 | 0.630 |
Why?
|
| Basilar Artery | 1 | 2020 | 34 | 0.630 |
Why?
|
| Embolization, Therapeutic | 2 | 2020 | 339 | 0.610 |
Why?
|
| Coronary Stenosis | 4 | 2016 | 41 | 0.600 |
Why?
|
| Rabbits | 8 | 2024 | 343 | 0.600 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2016 | 44 | 0.540 |
Why?
|
| Angina, Unstable | 2 | 2014 | 56 | 0.510 |
Why?
|
| Treatment Outcome | 19 | 2024 | 5832 | 0.480 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 74 | 0.480 |
Why?
|
| Everolimus | 7 | 2017 | 22 | 0.450 |
Why?
|
| Automation | 5 | 2016 | 55 | 0.420 |
Why?
|
| Molecular Imaging | 1 | 2014 | 52 | 0.410 |
Why?
|
| Cardiovascular Agents | 5 | 2017 | 107 | 0.410 |
Why?
|
| Thrombosis | 3 | 2020 | 207 | 0.370 |
Why?
|
| Subtraction Technique | 1 | 2012 | 24 | 0.360 |
Why?
|
| Humans | 35 | 2026 | 65872 | 0.330 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 715 | 0.310 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 1720 | 0.310 |
Why?
|
| Animals | 14 | 2024 | 21494 | 0.270 |
Why?
|
| Contrast Media | 3 | 2025 | 435 | 0.260 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2017 | 20 | 0.250 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 2327 | 0.240 |
Why?
|
| Atherosclerosis | 2 | 2021 | 162 | 0.240 |
Why?
|
| Cardiac Catheterization | 3 | 2017 | 293 | 0.240 |
Why?
|
| Male | 20 | 2025 | 31435 | 0.240 |
Why?
|
| Indocyanine Green | 2 | 2016 | 12 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 382 | 0.220 |
Why?
|
| Swine | 3 | 2021 | 398 | 0.220 |
Why?
|
| Prosthesis Design | 6 | 2016 | 223 | 0.220 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2017 | 96 | 0.220 |
Why?
|
| Wound Healing | 3 | 2014 | 193 | 0.210 |
Why?
|
| Miniaturization | 1 | 2024 | 10 | 0.210 |
Why?
|
| Fluorescent Dyes | 2 | 2016 | 204 | 0.200 |
Why?
|
| Iliac Artery | 2 | 2014 | 43 | 0.200 |
Why?
|
| Coronary Disease | 2 | 2015 | 247 | 0.200 |
Why?
|
| Middle Aged | 14 | 2025 | 18518 | 0.190 |
Why?
|
| Prosthesis Failure | 4 | 2017 | 78 | 0.180 |
Why?
|
| Paclitaxel | 2 | 2014 | 102 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 4 | 2016 | 124 | 0.180 |
Why?
|
| Aspirin | 2 | 2020 | 172 | 0.180 |
Why?
|
| Subarachnoid Space | 1 | 2022 | 15 | 0.180 |
Why?
|
| Arteritis | 1 | 2021 | 4 | 0.170 |
Why?
|
| PPAR alpha | 1 | 2021 | 33 | 0.170 |
Why?
|
| Absorbable Implants | 2 | 2017 | 10 | 0.170 |
Why?
|
| Heart | 1 | 2023 | 298 | 0.160 |
Why?
|
| Pancreatic Elastase | 1 | 2020 | 33 | 0.160 |
Why?
|
| Time Factors | 6 | 2025 | 3780 | 0.160 |
Why?
|
| Hyperplasia | 3 | 2021 | 92 | 0.160 |
Why?
|
| Aged | 13 | 2025 | 15155 | 0.160 |
Why?
|
| Angiography | 1 | 2020 | 154 | 0.150 |
Why?
|
| Cadaver | 1 | 2020 | 135 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2025 | 592 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 228 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 235 | 0.140 |
Why?
|
| Vascular Patency | 2 | 2015 | 135 | 0.120 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2020 | 45 | 0.120 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 22 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 76 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 61 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 2 | 2014 | 53 | 0.110 |
Why?
|
| Fibrosis | 1 | 2016 | 172 | 0.110 |
Why?
|
| Female | 14 | 2025 | 34459 | 0.110 |
Why?
|
| Observer Variation | 2 | 2015 | 217 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 330 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 2500 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2023 | 3340 | 0.100 |
Why?
|
| Vascular System Injuries | 1 | 2014 | 24 | 0.100 |
Why?
|
| Retreatment | 1 | 2013 | 43 | 0.090 |
Why?
|
| Models, Animal | 1 | 2013 | 243 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2012 | 55 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2013 | 208 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 113 | 0.090 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 78 | 0.090 |
Why?
|
| Medical Records | 1 | 2012 | 140 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2012 | 196 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 216 | 0.080 |
Why?
|
| Dogs | 2 | 2022 | 327 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2022 | 303 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1172 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1570 | 0.070 |
Why?
|
| Research Design | 1 | 2011 | 589 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 333 | 0.070 |
Why?
|
| Forecasting | 2 | 2019 | 231 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2013 | 2116 | 0.060 |
Why?
|
| Acute Disease | 2 | 2020 | 665 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 1196 | 0.050 |
Why?
|
| Intravital Microscopy | 1 | 2022 | 13 | 0.040 |
Why?
|
| Metals | 2 | 2013 | 65 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 5684 | 0.040 |
Why?
|
| Benzoxazoles | 1 | 2021 | 7 | 0.040 |
Why?
|
| Butyrates | 1 | 2021 | 16 | 0.040 |
Why?
|
| Microsurgery | 1 | 2022 | 55 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 131 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 202 | 0.040 |
Why?
|
| Arteries | 1 | 2020 | 88 | 0.040 |
Why?
|
| Adult | 4 | 2017 | 17595 | 0.040 |
Why?
|
| Hyperemia | 1 | 2017 | 14 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 70 | 0.030 |
Why?
|
| Adenosine | 1 | 2017 | 79 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 193 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1231 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2016 | 30 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 160 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 254 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2015 | 20 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 120 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 332 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 267 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 849 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 56 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 993 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 606 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 117 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 344 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 295 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2012 | 16 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 21 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 77 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 87 | 0.020 |
Why?
|
| Belgium | 1 | 2011 | 6 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1793 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 464 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 489 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 374 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 645 | 0.020 |
Why?
|